Moderna Peers Into Post-Pandemic Future For Respiratory Vaccines
Executive Summary
The company had its fourth vaccines day, where it talked about its strategy over the next few years for vaccines against COVID-19, RSV, flu and combinations thereof.
You may also be interested in...
The Top Five Pharma Stories Of 2023
The biopharma new year begins as the J.P. Morgan Healthcare Conference ends so here in no particular order, we take a look at five of the biggest stories of 2023, once again a year of highs and lows for the industry.
The Top Five Pharma Stories Of 2023
The biopharma new year begins as the J.P. Morgan Healthcare Conference ends so here in no particular order, Scrip takes a look at five of the biggest stories of 2023, once again a year of highs and lows for the industry.
A Stellar Launch For RSV Vaccine Arexvy Lifts GSK
GSK has enjoyed a better-than-expected launch for its RSV vaccine, but emphasized that it was still early days, and the firm is not altering its £3bn peak annual sales forecast for the product.